The HDAC inhibitor, 2-hexyl-4-pentylene acid (HPTA), demonstrated significant anti-tumor effects in a rat breast cancer model by leading to the increase in CXCL9/10 mRNA expression and protein levels following treatment (56). Here, CXCL9 is linked to neoplasm.